Advertisement

Journal of Gastrointestinal Cancer

, Volume 40, Issue 3–4, pp 101–108 | Cite as

Evaluation of Hypertension as a Marker of Bevacizumab Efficacy

  • Rebekah Ryanne WuEmail author
  • Peter A. Lindenberg
  • Rebecca Slack
  • Anne-Michelle Noone
  • John L. Marshall
  • Aiwu R. He
Original Research

Abstract

Background

Predictive factors for efficacy of vascular endothelial growth factor pathway-targeted therapies have not been identified or confirmed. Hypertension has been observed as a side effect to anti-vascular endothelial growth factor therapy. The goal of our study was to retrospectively assess if hypertension induced during treatment with bevacizumab was associated with clinical outcome in metastatic colorectal cancer patients treated with bevacizumab.

Patients and methods

We conducted a retrospective chart review of patients with colorectal cancer treated with bevacizumab at Lombardi Comprehensive Cancer Center from 2004 to 2008.

Results

Eighty-four patients with metastatic colorectal cancer were eligible. Eighteen patients (21%) developed grades 3 hypertension. Twelve patients (14%) developed grade 2 hypertension. Six patients (7%) developed grade 1 hypertension. Median overall survival (OS) was 29 months and progression-free survival (PFS) was 10 months. Patients with any grade hypertension while on bevacizumab had an adjusted hazard ratio for death of 0.32 (p = 0.03) and adjusted risk of progression of 51% (p = 0.02) compared to those without hypertension (HTN). When stratified by metastatic disease, patients presenting with metastases who developed HTN had better OS and PFS (p = 0.03 and 0.01.) Among patients without metastases at diagnosis, those with HTN on bevacizumab had better OS and PFS but results were not statistically significant (p = 0.60 and 0.62, respectively).

Conclusions

Our data indicate that bevacizumab-induced hypertension may represent an interesting prognostic factor for clinical outcome in advanced colorectal cancer patients receiving bevacizumab.

Keywords

bevacizumab colorectal cancer hypertension 

References

  1. 1.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.CrossRefPubMedGoogle Scholar
  2. 2.
    Fuchs CS, Marshall J, Mitchell E, et al. Randomized controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol. 2007;25:4779–86.CrossRefPubMedGoogle Scholar
  3. 3.
    Hochester HS, Hart LL, Ramanathan K, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol. 2008;26:3523–9.CrossRefGoogle Scholar
  4. 4.
    Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Giantonio BJ, Catalano PJ, Meropol N, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–44.CrossRefPubMedGoogle Scholar
  7. 7.
    Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97:981–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-a expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2006;24:217–27.CrossRefPubMedGoogle Scholar
  9. 9.
    Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49:186–93.CrossRefPubMedGoogle Scholar
  10. 10.
    Annex HTD, BH McKendall GR, et al. The viva trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003;107:1359–65.CrossRefPubMedGoogle Scholar
  11. 11.
    Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28:1779–803.CrossRefPubMedGoogle Scholar
  12. 12.
    Veronese ML, Flaherty KT, Townsend R, et al. Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: mechanisms of hypertension. J Clin Oncol. 2004;14(22 Suppl):2035.Google Scholar
  13. 13.
    Horowitz JR, Rivard A, van der Zee R, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Arterioscler Thromb Vasc Biol. 1997;17:2793–800.PubMedGoogle Scholar
  14. 14.
    Hood JD, Meininger CJ, Ziche M, Grander HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol Heart Circ Physiol. 1998;274:H1054–H58.Google Scholar
  15. 15.
    Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab: a crucial role of microcirculation. Ann Oncol. 2008;19:927–34.CrossRefPubMedGoogle Scholar
  16. 16.
    Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20:227–30.CrossRefPubMedGoogle Scholar
  17. 17.
    Bono P, Elfving H, Utriainen T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol. 2009;20:393–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Kohne C, Bajetta E, Lin E, et al. Final results of CONFIRM 2: A multinational, randomized, double-blinded phase III study in 2nd line patients with metastatic colorectal cancer receiving FOLFOX4 and PTK787/ZK 222584 or placebo. J Clin Oncol. 2007;18(25 Suppl):4033.Google Scholar
  19. 19.
    Miller KD, Chap LI, Holmes F, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improved survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2005;16(23 Suppl):2.Google Scholar
  21. 21.
    Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol. 2005;16(23 Suppl):3.Google Scholar
  22. 22.
    Kozloff M, Hainsworth J, Badarinath S, et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRite). J Clin Oncol. 2006;18(24 Suppl):3537.Google Scholar
  23. 23.
    Berry S, Cunningham D, Michael M, et al. Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and Capecitabine for metastatic colorectal cancer—first B E A trial. J Clin Oncol. 2006;18(24 Suppl):3534.Google Scholar
  24. 24.
    Agero AL Dusza SW, Benvenuto-Adrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Amer Acad Dermatol. 2006;55:657–70.CrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • Rebekah Ryanne Wu
    • 1
    Email author
  • Peter A. Lindenberg
    • 2
  • Rebecca Slack
    • 3
  • Anne-Michelle Noone
    • 3
  • John L. Marshall
    • 4
  • Aiwu R. He
    • 4
  1. 1.Department of Internal MedicineGeorgetown University HospitalWashingtonUSA
  2. 2.Department of OncologyWalter Reed Army HospitalWashingtonUSA
  3. 3.Department of Biostatistics, Bioinformatics, and Biomathematics and Lombardi Comprehensive Cancer CenterGeorgetown UniversityGeorgetownUSA
  4. 4.Department of Medicine and Oncology Lombardi Comprehensive Cancer CenterGeorgetown UniversityGeorgetownUSA

Personalised recommendations